Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
Heart failure is a major cause of morbidity and mortality worldwide. Here the authors show that subcutaneous administration of antisense oligonucleotides targeting PLN is an effective strategy in preclinical models of genetic cardiomyopathy and ischemia-driven heart failure.
Main Authors: | Niels Grote Beverborg, Daniela Später, Ralph Knöll, Alejandro Hidalgo, Steve T. Yeh, Zaher Elbeck, Herman H. W. Silljé, Tim R. Eijgenraam, Humam Siga, Magdalena Zurek, Malin Palmér, Susanne Pehrsson, Tamsin Albery, Nils Bomer, Martijn F. Hoes, Cornelis J. Boogerd, Michael Frisk, Eva van Rooij, Sagar Damle, William E. Louch, Qing-Dong Wang, Regina Fritsche-Danielson, Kenneth R. Chien, Kenny M. Hansson, Adam E. Mullick, Rudolf A. de Boer, Peter van der Meer |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-25439-0 |
Similar Items
-
Phospholamban - Identification of novel interaction partners
by: Kownatzki-Danger, Daniel
Published: (2020) -
An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation
by: Eduarde Rohner, et al.
Published: (2021-09-01) -
The targeting of phospholamban and sarcolipin to the endo / sarcoplasmic reticulum
by: Butler, John
Published: (2005) -
Die Bedeutung von Phospholamban Pentameren für die Phospholamban-Phosphorylierung und die Regulation der SERCA2a-Aktivität
by: Wittmann, Tanja
Published: (2014) -
The role of CaMKII regulation of phospholamban activity in heart disease
by: Alicia eMattiazzi, et al.
Published: (2014-01-01)